Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells

Journal of Biological Chemistry

Volumn 287, Issue 44, 2012, Pages 37109-37118

  Kotani, Norihiro ^a,b   Ishiura, Yoshihito ^b,c   Yamashita, Ryusuke ^b   Ohnishi, Tomoko ^b   Honke, Koichi ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B-CELL LYMPHOMA; FIBROBLAST GROWTH FACTOR RECEPTORS; PROLIFERATION INHIBITION; SIGNAL MOLECULES; TARGET MOLECULE; THERAPEUTIC ANTIBODIES;

BIOCHEMISTRY; BIOLOGY;

ANTIBODIES;

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; CASPASE 3; CD20 ANTIBODY; CD20 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RITUXIMAB; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; LYMPHOMA, B-CELL; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84868234379     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.404178     Document Type: Article

References (31)

1. White, C. A., Weaver, R. L., and Grillo-López, A. J. (2001) Antibodytargeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52, 125-145
2. Waldmann, T. A. (2003) Immunotherapy. Past, present, and future. Nat. Med. 9, 269-277
3. Cragg, M. S., French, R. R., and Glennie, M. J. (1999) Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11, 541-547
4. Press, O. W., Appelbaum, F., Ledbetter, J. A., Martin, P. J., Zarling, J., Kidd, P., and Thomas, E. D. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 69, 584-591
5. Maloney, D. G., Liles, T. M., Czerwinski, D. K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., and Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466
6. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., Newman, R. A., Hanna, N., and Anderson, D. R. (1994) Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445
7. Cartron, G., Watier, H., Golay, J., and Solal-Celigny, P. (2004) From the bench to the bedside. Ways to improve rituximab efficacy. Blood 104, 2635-2642
8. Deans, J. P., Robbins, S. M., Polyak, M. J., and Savage, J. A. (1998) Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J. Biol. Chem. 273, 344-348
9. Horejsí, V., Zhang, W., and Schraven, B. (2004) Transmembrane adaptor proteins. Organizers of immunoreceptor signaling. Nat. Rev. Immunol. 4, 603-616
10. Kotani, N., Gu, J., Isaji, T., Udaka, K., Taniguchi, N., and Honke, K. (2008) Biochemical visualization of cell surface molecular clustering in living cells. Proc. Natl. Acad. Sci. U.S.A. 105, 7405-7409
11. Honke, K., and Kotani, N. (2011) The enzyme-mediated activation of radical source reaction. A new approach to identify partners of a given molecule in membrane microdomains. J. Neurochem. 116, 690-695
12. Yamashita, R., Kotani, N., Ishiura, Y., Higashiyama, S., and Honke, K. (2011) Spatiotemporally regulated interaction between β1 integrin and ErbB4 that is involved in fibronectin-dependent cell migration. J. Biochem. 149, 347-355
13. Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jäger, C., Strein, P., Fertig, G., Friess, T., Schüll, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M. J., Poppema, S., Klein, C., and Umaña, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115, 4393-4402
14. Hofmeister, J. K., Cooney, D., and Coggeshall, K. M. (2000) Clustered CD20 induced apoptosis. Src family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26, 133-143
15. Deans, J. P., Li, H., and Polyak, M. J. (2002) CD20-mediated apoptosis. Signaling through lipid rafts. Immunology 107, 176-182
16. Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D. F., Chesi, M., and Bergsagel, P. L. (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103, 3521-3528
17. 0 arrest. J. Pharmacol. Exp. Ther. 332, 795-802
18. Baskar, S., Kwong, K. Y., Hofer, T., Levy, J. M., Kennedy, M. G., Lee, E., Staudt, L. M., Wilson, W. H., Wiestner, A., and Rader, C. (2008) Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14, 396-404
19. Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., and Bergsagel, P. L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16, 260-264
20. Chang, H., Stewart, A. K., Qi, X. Y., Li, Z. H., Yi, Q. L., and Trudel, S. (2005) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106, 353-355
21. Li, Z., Zhu, Y. X., Plowright, E. E., Bergsagel, P. L., Chesi, M., Patterson, B., Hawley, T. S., Hawley, R. G., and Stewart, A. K. (2001) The myelomaassociated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 97, 2413-2419
22. Jang, J. H., Shin, K. H., and Park, J. G. (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61, 3541-3543
23. van Rhijn, B. W., Lurkin, I., Radvanyi, F., Kirkels, W. J., van der Kwast, T. H., and Zwarthoff, E. C. (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61, 1265-1268
24. Zhang, Y., Hiraishi, Y., Wang, H., Sumi, K. S., Hayashido, Y., Toratani, S., Kan, M., Sato, J. D., and Okamoto, T. (2005) Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int. J. Cancer 117, 166-168
25. Chen, J., Lee, B. H., Williams, I. R., Kutok, J. L., Mitsiades, C. S., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., Coburn, A., Moore, S., Huntly, B. J., Fabbro, D., Anderson, K. C., Griffin, J. D., and Gilliland, D. G. (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24, 8259-8267
26. Tam, C. S., and Keating, M. J. (2010) Chemoimmunotherapy of chronic lymphocytic leukemia. Nat. Rev. Clin. Oncol. 7, 521-532
27. Sharkey, R. M., Karacay, H., Govindan, S. V., and Goldenberg, D. M. (2011) Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol. Cancer Ther. 10, 1072-1081
28. Alinari, L., Yu, B., Christian, B. A., Yan, F., Shin, J., Lapalombella, R., Hertlein, E., Lustberg, M. E., Quinion, C., Zhang, X., Lozanski, G., Muthusamy, N., Prtorius-Ibba, M., O'Connor, O. A., Goldenberg, D. M., Byrd, J. C., Blum, K. A., and Baiocchi, R. A. (2011) Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 117, 4530-4541
29. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H., Stilgenbauer, S., International Group of Investigators, and German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia. A randomized, open-label, phase 3 trial. Lancet 376, 1164-1174
30. Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., and Varns, C. (1999) Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17, 268-276
31. Stebbings, R., Poole, S., and Thorpe, R. (2009) Safety of biologics, lessons learned from TGN1412. Curr. Opin. Biotechnol. 20, 673-677